This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comSprint Communications Company LP v. WideOpenWest, Inc. et al., Case No. 1-18-cv-00361 (US District Court of Delaware) Sprint Communications filed lawsuits...
The 32-item Motor Function Measure (MFM32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular...
The European Commission has recently published a comprehensive package of regulatory reforms for the pharmaceutical sector in the European Union (EU), setting...
CRA is proud to support the New England region of the LSS Man & Woman of the year campaign, a philanthropic competition to support blood cancer research. Ned...
